^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Mantle Cell Lymphoma: Induction therapy…Other recommended regimen…Modified rituximab-HyperCVAD in patients older than 65 y
Secondary therapy:
CVAD
Source:
Excerpt:
Mantle Cell Lymphoma: Induction therapy…Other recommended regimen…Bendamustine + rituximab (category 2B)......Useful under Certain Circumstances…Bendamustine + rituximab + Cytarabine...Useful under Certain Circumstances…Bortezomib ± rituximab...Preferred Regimens…RDHA (rituximab, dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin)...NORDIC regimen (dose-intensified induction immunochemotherapy with rituximab + cyclophosphamide, vincristine, doxorubicin, prednisone [maxi-CHOP]) alternating with rituximab + high-dose cytarabine
Secondary therapy:
CHOP + cytarabine; carboplatin + cytarabine + dexamethasone; cytarabine + oxaliplatin + dexamethasone; bendamustine; cisplatin + cytarabine + dexamethasone; cytarabine + bortezomib + bendamustine
Source:
Excerpt:
Mantle Cell Lymphoma: Maintenance after HDT/ASCR…Maintenance rituximab every 8 weeks x 3 y (category 1)
